Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Section 4 of 6

Clinical evidence

323 evidence topics · 46 sources

Study summaries

AMPLITUDE

Objective
Location and study date
Study locations by country in the ClinicalTrials.gov record
CountryLocations listed in the record
United States“Alabama Locations”; “Arizona Locations”; “Arkansas Locations”; “California Locations”; “Connecticut Locations”; “District of Columbia Locations”; “Florida Locations”; “Georgia Locations”; “Illinois Locations”; “Indiana Locations”; “Iowa Locations”; “Kansas Locations”; “Louisiana Locations”; “Maryland Locations”; “Massachusetts Locations”; “Michigan Locations”; “Minnesota Locations”; “Mississippi Locations”; “Missouri Locations”; “Nevada Locations”; “New Jersey Locations”; “New Mexico Locations”; “New York Locations”; “North Carolina Locations”; “Ohio Locations”; “Pennsylvania Locations”; “Rhode Island Locations”; “South Carolina Locations”; “Tennessee Locations”; “Texas Locations”; “Virginia Locations”; “Washington Locations”; “Wisconsin Locations”
Belgium“Brussels, Belgium”; “Leuven, Belgium”
Brazil“Aracaju, Brazil”; “Belo Horizonte, Brazil”; “Botucatu, Brazil”; “Campinas, Brazil”; “Curitiba, Brazil”; “Fortaleza, Brazil”; “Goiânia, Brazil”; “Juiz de Fora, Brazil”; “Marília, Brazil”; “Monte Alegre, Brazil”; “Porto Alegre, Brazil”; “Recife, Brazil”; “Rio de Janeiro, Brazil”; “Salvador, Brazil”; “Santo André, Brazil”; “São José do Rio Preto, Brazil”; “São Paulo, Brazil”
Canada“Montreal, Canada”; “Toronto, Canada”
Colombia“Atlántico, Colombia”; “Bogotá, Colombia”; “Cali, Colombia”; “Cartagena, Colombia”; “Ibague, Colombia”; “Medellín, Colombia”
France“Créteil, France”; “Grenoble, France”; “Le Kremlin-Bicêtre, France”; “Limoges, France”; “Marseille, France”; “Paris, France”; “Pointe à Pitre, France”; “Saint-Ouen, France”; “Toulouse, France”
Ghana“Accra, Ghana”; “Cantonments, Ghana”; “Kumasi, Ghana”
Netherlands“Amsterdam, Netherlands”
Nigeria“Enugu, Nigeria”; “Ibadan, Nigeria”; “Idi-Araba, Nigeria”; “Ikeja, Nigeria”; “Lagos, Nigeria”
Portugal“Amadora, Portugal”; “Lisbon, Portugal”; “Loures, Portugal”
Puerto Rico“Mayagüez, Puerto Rico, 06680”; “Rio Piedras, Puerto Rico, 00935”; “San Juan, Puerto Rico, 00917”
Spain“Barcelona, Spain”; “Córdoba, Spain”; “Madrid, Spain”; “Seville, Spain”
United Kingdom“Basildon, United Kingdom”; “Bellshill, United Kingdom”; “Birmingham, United Kingdom”; “Carshalton, United Kingdom”; “Leicester, United Kingdom”; “London, United Kingdom”; “Manchester, United Kingdom”; “Nottingham, United Kingdom”
Study design
Independent data monitoring committee in the ClinicalTrials.gov data summarized by the EU register mirror
Eligibility criteria
Part A inclusion criteria: genotype, age, body size, proteinuria, and kidney function in the EU register record

“Subject has an APOL1 genotype of G1/G1, G2/G2, or G1/G2 obtained with a Vertex designated investigational clinical study assay.” (opens the source at this quote in a new tab)

“For Phase 2, subjects must be between the ages of 18 and 65 years at time of signing first ICF, inclusive. For Phase 3, subjects must be between the ages of 12 and 65 years at time of signing first ICF, inclusive.” (opens the source at this quote in a new tab)

“Pediatric subjects may be enrolled only after IDMC review of Phase 2 data is completed, the Phase 3 dose is selected, and a recommendation by the IDMC on the inclusion of pediatric subjects is made.” (opens the source at this quote in a new tab)

“Up to approximately 15% of the total number of subjects planned for enrollment may be >61 to ≤65 years of age at time of signing first ICF, inclusive.” (opens the source at this quote in a new tab)

“A BMI of 18 to 45 kg/m2, inclusive, and a total body weight ≥40 kg.” (opens the source at this quote in a new tab)

“A UPCR of ≥0.7 g/g to <10 g/g in the first morning void based on the average of 3 measurements collected on 3 separate days within a 7-day period, during the Screening Period.” (opens the source at this quote in a new tab)

“Estimated glomerular filtration rate (eGFR) ≥25 to < 75 mL/min/1.73 m2 during the Screening Period” (opens the source at this quote in a new tab)

Treatment
Investigational medicinal product and placebo in the EU register record
FieldQuoted record
Test product“VX-147 film-coated tablet”
Maximum daily dose“45 mg milligram(s)”
Maximum total dose“4860 mg milligram(s)”
Maximum duration of treatment“108 week(s)”
Orphan designation number“EMA/OD/0000090156”
Placebo“VX-147, Coated Placebo Tablet”
Study outcomes
Rationale for using percent change in UPCR at week 48 and eGFR slope as the primary endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary: study limitations

As of November 2026, no efficacy or safety results of AMPLITUDE have been published or posted: the registry record shows 522 participants enrolled, and the company states that data from the week 48 interim analysis are expected in early 2027. The only participant-level data reported are the APOL1 genotype distribution, mean age (42.7 years), and mean eGFR (42.8 mL/min/1.73 m2) of the 64 participants dosed as of the 2025 abstract; the dose-selection results of that portion and its safety data have not been reported. The accelerated approval pathway rests on the week 48 interim analysis of percent change in UPCR and eGFR slope, two surrogate endpoints; the final analysis of eGFR slope requires at least 2 years of eGFR data, and the composite clinical outcome (sustained eGFR decline of at least 30%, end-stage kidney disease, or death) is a secondary endpoint. The supporting surrogate-endpoint evidence comes mainly from other kidney diseases: the EMA notes that for rare diseases “support of efficacy may need to be provided by additional endpoints”, a 2025 review states for proteinuria short of complete remission in FSGS that “further work is needed to determine how such an endpoint should be defined”, and the only analysis specific to APOL1-mediated kidney disease is a real-world analysis of 128 participants. Eligibility required UPCR of 0.7 to less than 10 g/g and eGFR of 25 to less than 75 mL/min/1.73 m2 and excluded people with diabetes, transplantation, uncontrolled hypertension, or another known cause of kidney disease, so the results will not describe people with modest proteinuria or type 2 diabetes, whom the company describes as “populations not being studied in the AMPLITUDE trial”. The registered age range differs between records: the ClinicalTrials.gov record lists 10 to 65 years, and the EU register inclusion criteria list 12 to 65 years for phase 3. The registry lists 314 locations in 13 countries and territories, including the United States. In Part B, participants who complete Part A receive inaxaplin for an additional 96 weeks without a placebo group, and the definitions of the analysis populations have not been published.

VX19-147-101

Objective
Location and study date
Study design
Design details in the ClinicalTrials.gov record
FieldQuoted record
Primary purpose“Treatment”
Allocation“N/A”
Interventional model“Single Group Assignment”
Masking“None (Open Label)”
Phase“Phase 2”
Enrollment“16”
Eligibility criteria
Inclusion criteria in the protocol: biopsy, stable background therapy, eGFR, and UPCR
Treatment
Study outcomes
Rationale for using percent change in UPCR as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants by cohort in the posted results
MeasureQuoted record
Enrollment (actual)“16”
Started“16”
Cohort 1“3”
Cohort 2“13”
AUC0-24hr, overall number of participants analyzed“13”
Description of analysis sets
Results
Participant disposition
Participant flow in the posted results
MilestoneQuoted record
Started“16”
Cohort 1“3”
Cohort 2“13”
Completed“15”
Not completed“1”
Reason not completed“Withdrawal of consent (not due to adverse event)”
Baseline characteristics
Demographic and clinical characteristics at baseline (Table 1)
CharacteristicTotal (N=16)Nephrotic-range proteinuria (N=3)Subnephrotic-range proteinuria (N=13)
Age, years, mean ±SD“38.8±14.5”“45.0±10.5”“37.3±15.2”
Male, no. (%)“7 (44)”“1 (33)”“6 (46)”
Female, no. (%)“9 (56)”“2 (67)”“7 (54)”
APOL1 genotype G1/G1, no. (%)“9 (56)”“3 (100)”“6 (46)”
APOL1 genotype G2/G2, no. (%)“1 (6)”“0”“1 (8)”
APOL1 genotype G1/G2, no. (%)“6 (38)”“0”“6 (46)”
Body-mass index, mean ±SD“29.6±6.4”“32.7±6.4”“28.9±6.4”
Urinary protein-to-creatinine ratio, mean ±SD“2.08±0.90”“3.47±1.07”“1.77±0.49”
Estimated GFR, ml/min/1.73 m2, mean ±SD“51.2±14.0”“51.4±22.2”“51.2±12.8”
ACE inhibitor ≥28 days before day 1, no. (%)“8 (50)”“1 (33)”“7 (54)”
Angiotensin-receptor blocker ≥28 days before day 1, no. (%)“7 (44)”“3 (100)”“4 (31)”
Immunosuppressants ≥28 days before day 1, no. (%)“4 (25)”“1 (33)”“3 (23)”
Race and ethnicity in the posted results
CharacteristicCohort 1 (N=3)Cohort 2 (N=13)
Black or African American“3”“13”
White“0”“0”
Not Hispanic or Latino“3”“13”
Efficacy results
Primary endpoint: percent change from baseline in UPCR at week 13 (Table 2)
MeasureTotal (N=13)Nephrotic-range proteinuria (N=3)Subnephrotic-range proteinuria (N=10)
Mean UPCR at baseline, ±SD“2.21±0.95”“3.47±1.07”“1.84±0.52”
Mean UPCR at week 13, ±SD“1.27±0.73”“1.83±0.58”“1.10±0.71”
Geometric percent change from baseline at week 13 (95% CI)“−47.6 (−60.0 to −31.3)”“−47.7 (−70.1 to −8.5)”“−47.5(−63.4 to −24.6)”
Pharmacokinetics: AUC0-24h at week 5 (secondary outcome)
Health-related quality of life and patient-reported outcomes
SF-36 results

No evidence found.

Safety results
Adverse events (Table 3)
Event, no. (%)Total (N=16)Nephrotic-range proteinuria (N=3)Subnephrotic-range proteinuria (N=13)
Any adverse event“15 (94)”“3 (100)”“12 (92)”
Mild“7 (44)”“1 (33)”“6 (46)”
Moderate“8 (50)”“2 (67)”“6 (46)”
Serious adverse event“1 (6)”“0”“1 (8)”
Headache“4 (25)”“1 (33)”“3 (23)”
Back pain“3 (19)”“0”“3 (23)”
Nausea“3 (19)”“1 (33)”“2 (15)”
Decrease in blood bicarbonate level“2 (12)”“0”“2 (15)”
Diarrhea“2 (12)”“1 (33)”“1 (8)”
Dizziness“2 (12)”“0”“2 (15)”
Dyspepsia“2 (12)”“0”“2 (15)”
Fatigue“2 (12)”“0”“2 (15)”
Deaths, serious adverse events, and other adverse events in the posted results
Measure, affected / at risk (%)Cohort 1Cohort 2Total
All-cause mortality“0/3 (0.00%)”“0/13 (0.00%)”“0/16 (0.00%)”
Serious adverse events, total“0/3 (0.00%)”“1/13 (7.69%)”“1/16 (6.25%)”
Other (not including serious) adverse events, total“3/3 (100.00%)”“12/13 (92.31%)”“15/16 (93.75%)”
Adverse events in investigations and cardiac disorders in the posted results
EventTotal, affected / at risk (%)
Blood bicarbonate decreased“2/16 (12.50%)”
Blood creatine phosphokinase increased“1/16 (6.25%)”
Electrocardiogram ST segment depression“1/16 (6.25%)”
Gamma-glutamyltransferase increased“1/16 (6.25%)”
Transaminases increased“1/16 (6.25%)”
Palpitations“1/16 (6.25%)”
Study limitations
Summary: study limitations

VX19-147-101 was a single-group, open-label study without a placebo group; the protocol states that a placebo arm was omitted because of a “very low likelihood of spontaneous remission”. Sixteen participants were enrolled, and the primary analysis included the 13 participants with at least 80% adherence; the planned sample size of 10 was chosen for the precision of the geometric mean estimate, without a power calculation. Treatment lasted 13 weeks, and the off-treatment follow-up (part B) included 9 participants. The primary endpoint was the percent change from baseline in the urinary protein-to-creatinine ratio at week 13, and the secondary endpoints were safety and pharmacokinetics. Eligibility required biopsy-proven focal segmental glomerulosclerosis, two APOL1 variants, age 18 to 65 years, and an estimated GFR of at least 30 mL/min/1.73 m2 (±10%), so other APOL1-mediated kidney disease phenotypes were not studied; only 3 participants had nephrotic-range proteinuria. All 16 participants were Black or African American and were enrolled at sites in France, the United Kingdom, and the United States. The protocol listed SF-36 as an exploratory endpoint, and no SF-36 results were located in the published report or the posted results.

AMPLIFIED

Objective
Location and study date
Study locations by state in the ClinicalTrials.gov record
StateLocations listed in the record
Alabama“Huntsville, Alabama, United States, 35805”
Florida“Hollywood, Florida, United States, 33023”; “Lauderdale Lakes, Florida, United States, 33313”; “Miami, Florida, United States, 33136”; “Orlando, Florida, United States, 32806”
Georgia“Columbus, Georgia, United States, 31904”; “Decatur, Georgia, United States, 30030”; “Fayetteville, Georgia, United States, 30214”; “Lawrenceville, Georgia, United States, 30046”; “Savannah, Georgia, United States, 31406”
Louisiana“Baton Rouge, Louisiana, United States, 70808”; “Metairie, Louisiana, United States, 70006”; “New Orleans, Louisiana, United States, 70121”; “Shreveport, Louisiana, United States, 71101”
Maryland“Silver Spring, Maryland, United States, 20901”
Mississippi“Columbus, Mississippi, United States, 39705”; “Tupelo, Mississippi, United States, 38801”
Nevada“Las Vegas, Nevada, United States, 89107”
New Jersey“Newark, New Jersey, United States, 07102”; “Newark, New Jersey, United States, 07103”
New York“Laurelton, New York, United States, 11413”; “New York, New York, United States, 10037”
North Carolina“Cary, North Carolina, United States, 27511”; “Chapel Hill, North Carolina, United States, 27599-7155”; “Durham, North Carolina, United States, 27710”; “New Bern, North Carolina, United States, 28562”
Pennsylvania“Philadelphia, Pennsylvania, United States, 19140”
South Carolina“Columbia, South Carolina, United States, 29203”; “Spartanburg, South Carolina, United States, 29306”
Texas“Dallas, Texas, United States, 75230”; “Dallas, Texas, United States, 75237”; “Dallas, Texas, United States, 75246”; “Dallas, Texas, United States, 75390”; “Houston, Texas, United States, 77054”
Virginia“Norfolk, Virginia, United States, 23504”
Study design
Design details in the ClinicalTrials.gov record
FieldRegistry value
Study type“Interventional”
Phase“Phase 2”
Primary purpose“Treatment”
Allocation“N/A”
Interventional model“Single Group Assignment”
Masking“None (Open Label)”
Eligibility criteria
Age, sex, and healthy volunteers in the ClinicalTrials.gov record
FieldRegistry value
Ages eligible for study“18 Years to 67 Years”
Sexes eligible for study“All”
Accepts healthy volunteers“No”
Treatment
Study outcomes
Rationale for using percent change in UACR as the primary endpoint
Albuminuria change and kidney outcomes in APOL1-mediated kidney disease

“Recently, proteinuria has been accepted as a surrogate end point for clinical trials in focal segmental glomerulosclerosis (FSGS) ang IgA nephropathy. However, proteinuria has not been evaluated in Apolipoprotein L1 (APOL1)-mediated kidney disease (AMKD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Real world data (RWD) analysis of 128 patients of African ancestry with APOL1 high risk genotypes, without diabetes, enrolled in the Million Veteran Program (MVP; n=109) or the biorepository at Vanderbilt University (BioVU; n=19), who had urine albumin-creatinine ratio (UACR) >= 420 mg/g (PCR~0.9 g/g) with a concurrent GFR value.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“It was estimated that a 50% reduction of UACR at 12 months was associated with a 28% reduction in the kidney composite endpoint (adjusted hazard ratio [aHR]=0.72; 95% confidence interval [CI]:0.59−0.88; p=0.002), and a 38% reduction in the risk of ESKD (aHR=0.62; 95% CI:0.49−0.80; p<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Changes in UACR at 12 months significantly modify the rate of decline of GFR over 24 months and clinically meaningful endpoints, supporting the use of UACR changes as surrogate endpoint in AMKD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Statistical analysis description
Number of participants (Planned and analyzed)
Participants dosed and analyzed by cohort stated with the results
CohortEnrolled and dosedEfficacy analysisOn treatment with a week 13 assessment
Cohort 1: AMKD with modest proteinuria“N=23”“N=22”“18 and 14 people in cohort 1 and 2, respectively”
Cohort 2: AMKD with type 2 diabetes“N=18”“N=17”“18 and 14 people in cohort 1 and 2, respectively”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline UACR and UPCR by cohort
MeasureCohort 1: AMKD with modest proteinuriaCohort 2: AMKD with type 2 diabetes
Mean baseline UACR g/g (standard deviation)“0.28 (0.09)”“0.67 (0.87)”
Mean baseline UPCR g/g (standard deviation)“0.46 (0.20)”“1.12 (1.51)”
Efficacy results
Percent change in UACR and UPCR at week 13 by cohort
EndpointCohort 1: AMKD with modest proteinuriaCohort 2: AMKD with type 2 diabetes
Primary: geometric mean percent change in UACR at week 13 (95% confidence interval)“-42.7%”; “(-58.3%, -21.1%)”“-17.3%”; “(-36.3%, 7.2%)”
Other: geometric mean percent change in UPCR at week 13 (95% confidence interval)“-44.7%”; “(-60.9%, -21.9%)”“-25.4%”; “(-45.1%, 1.4%)”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary: study limitations

AMPLIFIED was a single-arm, open-label study without a placebo or active comparator, so each cohort's result is a change from baseline over 13 weeks of inaxaplin 45 mg once daily added to “optimized standard of care”. Of 41 participants enrolled and dosed (23 in cohort 1 and 18 in cohort 2), 39 were in the efficacy analyses, and the week 13 analyses included 18 and 14 participants; the registry lists an actual enrollment of 42. The 95% confidence intervals “were generated post-hoc”, and in cohort 2 they include no change for both UACR (-36.3% to 7.2%) and UPCR (-45.1% to 1.4%). The design abstract planned 45 participants, including a third cohort of 15 participants with sickle cell disease, HIV, or lupus nephritis, which the results announcement does not report. The registry lists UACR as the only efficacy outcome measure, and UPCR is reported as an “other” endpoint. All 35 registered sites are in the United States, eligibility was limited to ages 18 to 67 years with eGFR of at least 25 mL/min/1.73 m2, and the only baseline characteristics reported are mean UACR and UPCR by cohort. The study measured no kidney function outcome. The AMKD-specific analysis supporting UACR change as a surrogate endpoint used 12-month changes in 128 participants without diabetes and with UACR of at least 420 mg/g, a range that excludes the cohort 1 eligibility range (UACR at least 100 to below 420 mg/g) and the cohort 2 population. As of 2026-11-15 the results are available only from company communications: the registry shows “No Results Posted”, and no peer-reviewed publication or congress presentation of the results was identified.

VX18-147-001

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using safety and tolerability assessments as the primary endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics pooled across Study 1 and Study 2
CharacteristicPlacebo (N = 44)Inaxaplin total (N = 134)
Male, n (%)“41 (93.2)”View highlighted excerpt for this quote“128 (95.5)”View highlighted excerpt for this quote
Female, n (%)“3 (6.8)”View highlighted excerpt for this quote“6 (4.5)”View highlighted excerpt for this quote
Age (years), mean (±SD)“36.7 (11.3)”View highlighted excerpt for this quote“36.6 (11.6)”View highlighted excerpt for this quote
BMI (kg/m2), mean (±SD)“27.07 (3.14)”View highlighted excerpt for this quote“26.22 (3.30)”View highlighted excerpt for this quote
White, n (%)“30 (68.2)”View highlighted excerpt for this quote“94 (70.1)”View highlighted excerpt for this quote
Black or African American, n (%)“12 (27.3)”View highlighted excerpt for this quote“32 (23.9)”View highlighted excerpt for this quote
Asian, n (%)“0”View highlighted excerpt for this quote“1 (0.7)”View highlighted excerpt for this quote
American Indian or Alaska Native, n (%)“0”View highlighted excerpt for this quote“3 (2.2)”View highlighted excerpt for this quote
Multiracial, n (%)“1 (2.3)”View highlighted excerpt for this quote“4 (3.0)”View highlighted excerpt for this quote
Other race, n (%)“1 (2.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Hispanic or Latino, n (%)“10 (22.7)”View highlighted excerpt for this quote“21 (15.7)”View highlighted excerpt for this quote
Not Hispanic or Latino, n (%)“34 (77.3)”View highlighted excerpt for this quote“113 (84.3)”View highlighted excerpt for this quote
Efficacy results
Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results
Adverse events in the MAD cohorts of Study 1
n (%)Placebo (N = 9)Inaxaplin 15 mg once daily (N = 9)Inaxaplin 15 mg twice daily (N = 9)Inaxaplin 45 mg once daily (N = 9)Inaxaplin total (N = 27)
Participants with any AEs“2 (22.2)”View highlighted excerpt for this quote“4 (44.4)”View highlighted excerpt for this quote“5 (55.6)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“10 (37.0)”View highlighted excerpt for this quote
Mild AEs“2 (22.2)”View highlighted excerpt for this quote“4 (44.4)”View highlighted excerpt for this quote“5 (55.6)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“10 (37.0)”View highlighted excerpt for this quote
Moderate AEs“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Participants with SAEs“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
AEs leading to treatment discontinuation“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“1 (3.7)”View highlighted excerpt for this quote
Headache“0”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“2 (22.2)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (11.1)”View highlighted excerpt for this quote
Fatigue“1 (11.1)”View highlighted excerpt for this quote“2 (22.2)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (7.4)”View highlighted excerpt for this quote
Cough“0”View highlighted excerpt for this quote“3 (33.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (11.1)”View highlighted excerpt for this quote
Dyspepsia“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (33.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (11.1)”View highlighted excerpt for this quote
Constipation“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (22.2)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (7.4)”View highlighted excerpt for this quote
Oropharyngeal pain“0”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (7.4)”View highlighted excerpt for this quote
Throat irritation“0”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (7.4)”View highlighted excerpt for this quote
Rhinorrhea“1 (11.1)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3.7)”View highlighted excerpt for this quote
Sneezing“1 (11.1)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3.7)”View highlighted excerpt for this quote
Study limitations
Summary: study limitations

VX18-147-001 enrolled healthy adults, so its safety findings do not describe people with APOL1-mediated kidney disease. Multiple dosing lasted 14 days, and each MAD group of Study 1 had 9 participants receiving inaxaplin (15 mg once daily, 15 mg twice daily, or 45 mg once daily) and 9 receiving pooled placebo. Across both phase 1 studies, 128 of 134 participants receiving inaxaplin (95.5%) were male, which the authors attribute to the exclusion of women of childbearing potential. The publication reports demographics, disposition, and the overall adverse event table pooled across Study 1 and Study 2, and gives the pharmacokinetic parameter estimates, including the midazolam interaction results, only in online supplementary tables. The trials were designed and funded by Vertex Pharmaceuticals, and four of the authors are Vertex employees who own stock or stock options in the company.

VX20-147-008

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using safety and tolerability assessments as the primary endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics pooled across Study 1 and Study 2
CharacteristicPlacebo (N = 44)Inaxaplin total (N = 134)
Male, n (%)“41 (93.2)”View highlighted excerpt for this quote“128 (95.5)”View highlighted excerpt for this quote
Female, n (%)“3 (6.8)”View highlighted excerpt for this quote“6 (4.5)”View highlighted excerpt for this quote
Age (years), mean (±SD)“36.7 (11.3)”View highlighted excerpt for this quote“36.6 (11.6)”View highlighted excerpt for this quote
BMI (kg/m2), mean (±SD)“27.07 (3.14)”View highlighted excerpt for this quote“26.22 (3.30)”View highlighted excerpt for this quote
White, n (%)“30 (68.2)”View highlighted excerpt for this quote“94 (70.1)”View highlighted excerpt for this quote
Black or African American, n (%)“12 (27.3)”View highlighted excerpt for this quote“32 (23.9)”View highlighted excerpt for this quote
Asian, n (%)“0”View highlighted excerpt for this quote“1 (0.7)”View highlighted excerpt for this quote
American Indian or Alaska Native, n (%)“0”View highlighted excerpt for this quote“3 (2.2)”View highlighted excerpt for this quote
Multiracial, n (%)“1 (2.3)”View highlighted excerpt for this quote“4 (3.0)”View highlighted excerpt for this quote
Other race, n (%)“1 (2.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Hispanic or Latino, n (%)“10 (22.7)”View highlighted excerpt for this quote“21 (15.7)”View highlighted excerpt for this quote
Not Hispanic or Latino, n (%)“34 (77.3)”View highlighted excerpt for this quote“113 (84.3)”View highlighted excerpt for this quote
Efficacy results
Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results
Adverse events in the completed MAD cohorts of Study 2
n (%)Placebo (N = 9)Inaxaplin 60 mg once daily (N = 9)Inaxaplin 90 mg once daily (N = 9)Inaxaplin 120 mg once daily (N = 9)Inaxaplin total (N = 27)
Participants with any AEs“5 (55.6)”View highlighted excerpt for this quote“6 (66.7)”View highlighted excerpt for this quote“3 (33.3)”View highlighted excerpt for this quote“3 (33.3)”View highlighted excerpt for this quote“12 (44.4)”View highlighted excerpt for this quote
Mild AEs“4 (44.4)”View highlighted excerpt for this quote“6 (66.7)”View highlighted excerpt for this quote“3 (33.3)”View highlighted excerpt for this quote“3 (33.3)”View highlighted excerpt for this quote“12 (44.4)”View highlighted excerpt for this quote
Moderate AEs“1 (11.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Participants with SAEs“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
AEs leading to treatment discontinuation“0”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3.7)”View highlighted excerpt for this quote
Headache“0”View highlighted excerpt for this quote“2 (22.2)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“2 (22.2)”View highlighted excerpt for this quote“5 (18.5)”View highlighted excerpt for this quote
Palpitations“1 (11.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3.7)”View highlighted excerpt for this quote
Abdominal pain“1 (11.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“1 (3.7)”View highlighted excerpt for this quote
Diarrhea“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“2 (7.4)”View highlighted excerpt for this quote
Study limitations
Summary: study limitations

VX20-147-008 enrolled healthy adults at one United States site and tested single doses of 90 to 165 mg and multiple doses of 60 to 120 mg once daily, above the 15 mg and 45 mg once daily doses being evaluated in the phase 2/3 trial, with multiple dosing limited to 14 days. Two of its MAD cohorts were stopped early by sponsor decision: 12 participants after an ECG finding attributed to equipment malfunction and 9 participants because of possible COVID-19 exposure, and both cohorts were repeated with new participants. The Study 2 MAD adverse event table therefore excludes these cohorts and has 9 participants in each dose group and 9 receiving pooled placebo, while the pooled adverse event table includes them. Across both phase 1 studies, 128 of 134 participants receiving inaxaplin (95.5%) were male, which the authors attribute to the exclusion of women of childbearing potential. Pharmacokinetic parameter estimates appear only in online supplementary tables, and the trials were designed and funded by Vertex Pharmaceuticals.

VX19-147-007

Objective
Location and study date
Study dates and status in the registry record
FieldRegistry entry
Recruitment status“Completed”
Study start (actual)“2023-06-12”
Primary completion (actual)“2024-06-12”
Study completion (actual)“2024-06-12”
First posted“2023-05-18”
Last update posted“2024-07-12”
Other study ID numbers“VX19-147-007”
Study design
Design details in the registry record
FieldRegistry entry
Study type“Interventional”
Phase“Phase 1”
Primary purpose“Basic Science”
Allocation“Randomized”
Interventional model“Sequential Assignment”
Masking“None (Open Label)”
Eligibility criteria
Age range and healthy volunteers
FieldRegistry entry
Ages eligible“18 Years to 80 Years”
Sexes eligible“All”
Accepts healthy volunteers“Yes”
Treatment
Study outcomes
Rationale for using plasma cmax and AUC0-inf as the primary endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment in the registry record
FieldRegistry entry
Enrollment (actual)“16”
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results
Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results
Study limitations
Summary: study limitations

VX19-147-007 gave a single 45 mg dose to 16 participants: 8 with severe renal impairment (estimated glomerular filtration rate below 30 mL/min and not on dialysis) and 8 matched healthy participants. The results are available only as a congress abstract, which reports the geometric least squares mean ratio as “<120%” without point estimates or confidence intervals and reports safety only as “generally safe and well tolerated”. The ClinicalTrials.gov record lists no posted results. Participants on dialysis and multiple-dose exposure were not studied, and five of the six abstract authors list a Vertex Pharmaceuticals affiliation.

VX20-147-006

Objective
Location and study date
Study dates and status in the registry record
FieldRegistry entry
Recruitment status“Completed”
Study start (actual)“2024-08-02”
Primary completion (actual)“2024-12-20”
Study completion (actual)“2024-12-20”
First posted“2024-07-31”
Last update posted“2025-01-20”
Other study ID numbers“VX20-147-006”
Study design
Design details in the registry record
FieldRegistry entry
Study type“Interventional”
Phase“Phase 1”
Primary purpose“Basic Science”
Allocation“Non-Randomized”
Interventional model“Parallel Assignment”
Masking“None (Open Label)”
Eligibility criteria
Age range and healthy volunteers
FieldRegistry entry
Ages eligible“18 Years to 75 Years”
Sexes eligible“All”
Accepts healthy volunteers“Yes”
Treatment
Study outcomes
Rationale for using plasma cmax and AUC0-inf as the primary endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment in the registry record
FieldRegistry entry
Enrollment (actual)“36”
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results
Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results
Study limitations
Summary: study limitations

VX20-147-006 gave a single 45 mg dose to 36 participants: 10 with mild (Child-Pugh 5 to 6) and 10 with moderate (Child-Pugh 7 to 9) hepatic impairment, and 16 matched healthy participants. The abstract's conclusion of no clinically meaningful difference extends only “up to and including a CP score of 7”; one participant with a Child-Pugh score of 9 had an AUC about 2.2-fold higher than participants with scores of 7 or below. Severe hepatic impairment (Child-Pugh Class C) was outside the eligibility criteria. The results are available only as a congress abstract, which reports the geometric least squares mean ratio as “<125%” without point estimates or confidence intervals, and the ClinicalTrials.gov record lists no posted results.

VX22-147-010

Objective
Location and study date
Study dates and status in the registry record
FieldRegistry entry
Recruitment status“Completed”
Study start (actual)“2023-07-19”
Primary completion (actual)“2023-09-02”
Study completion (actual)“2023-09-02”
First posted“2023-07-21”
Last update posted“2023-09-13”
Other study ID numbers“VX22-147-010”
Study design
Design details in the registry record
FieldRegistry entry
Study type“Interventional”
Phase“Phase 1”
Primary purpose“Treatment”
Allocation“Randomized”
Interventional model“Crossover Assignment”
Masking“None (Open Label)”
Eligibility criteria
Age range and healthy volunteers
FieldRegistry entry
Ages eligible“18 Years to 55 Years”
Sexes eligible“All”
Accepts healthy volunteers“Yes”
Treatment
Study outcomes
Rationale for using relative bioavailability and food effect on cmax and AUC0-inf as the primary endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment in the registry record
FieldRegistry entry
Enrollment (actual)“21”
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results

No evidence found.

Study limitations
Summary: study limitations

VX22-147-010 enrolled 21 healthy adults aged 18 to 55 years at one United States site and compared a test tablet with a reference tablet, and the test tablet fed with fasted, in a three-period crossover with 5-day washouts. The study was completed on 2023-09-02, but the ClinicalTrials.gov record lists no posted results, and no publication or congress abstract reporting its results was identified. The registry record does not state the dose or the composition of the test meal.